These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34024744)

  • 1. Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis.
    Bhutani D; Pan S; Latif F; Goldsmith RL; Saith SE; Mapara MY; Chakraborty R; Lentzsch S; Maurer MS
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):545-548. PubMed ID: 34024744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
    Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
    JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
    Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
    Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
    Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
    Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.
    Nicol M; Deney A; Lairez O; Vergaro G; Emdin M; Carecci A; Inamo J; Montfort A; Neviere R; Damy T; Harel S; Royer B; Baudet M; Cohen-Solal A; Arnulf B; Logeart D
    Eur J Heart Fail; 2021 Feb; 23(2):231-239. PubMed ID: 33006180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients -  single center experience].
    Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
    Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiopulmonary Exercise Testing in Evaluating Transthyretin Amyloidosis.
    Patel RK; Bandera F; Venneri L; Porcari A; Razvi Y; Ioannou A; Chacko L; Martinez-Naharro A; Rauf MU; Knight D; Brown J; Petrie A; Wechalekar A; Whelan C; Lachmann H; Muthurangu V; Guazzi M; Hawkins PN; Gillmore JD; Fontana M
    JAMA Cardiol; 2024 Apr; 9(4):367-376. PubMed ID: 38446436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different NT-proBNP circulating levels for different types of cardiac amyloidosis.
    Perfetto F; Bergesio F; Grifoni E; Fabbri A; Ciuti G; Frusconi S; Angelotti P; Spini V; Cappelli F
    J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):810-7. PubMed ID: 26765991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study.
    Ingebrigtsen A; Saeed S; Larsen TH; Reikvam H
    Scand J Clin Lab Invest; 2024 May; 84(3):193-201. PubMed ID: 38709651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
    Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
    Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems.
    Cappelli F; Martone R; Gabriele M; Taborchi G; Morini S; Vignini E; Allinovi M; Di Gioia M; Bartolini S; Di Mario C; Perfetto F
    Can J Cardiol; 2020 Mar; 36(3):424-431. PubMed ID: 32145869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters.
    Lei C; Zhu X; Hsi DH; Wang J; Zuo L; Ta S; Yang Q; Xu L; Zhao X; Wang Y; Sun S; Liu L
    BMC Cardiovasc Disord; 2021 Jan; 21(1):43. PubMed ID: 33478398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.
    Cappelli F; Baldasseroni S; Bergesio F; Perlini S; Salinaro F; Padeletti L; Attanà P; Paoletti Perini A; Moggi Pignone A; Grifoni E; Fabbri A; Marchionni N; Gensini GF; Perfetto F
    Clin Cardiol; 2015 Feb; 38(2):69-75. PubMed ID: 25645201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
    Dispenzieri A; Gertz MA; Kyle RA; Lacy MQ; Burritt MF; Therneau TM; Greipp PR; Witzig TE; Lust JA; Rajkumar SV; Fonseca R; Zeldenrust SR; McGregor CG; Jaffe AS
    J Clin Oncol; 2004 Sep; 22(18):3751-7. PubMed ID: 15365071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiopulmonary Exercise Physiology in AL Amyloidosis Patients with Cardiac Involvement and Its Association with Cardiac Imaging Parameters.
    Briasoulis A; Theodorakakou F; Rempakos A; Petropoulos I; Gavriatopoulou M; Androulakis E; Stamatelopoulos K; Kallianos A; Trakada G; Dimopoulos MA; Kastritis E
    J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36143084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of usefulness between exercise capacity and echocardiographic indexes of left ventricular function in cardiac amyloidosis.
    Trikas A; Rallidis L; Hawkins P; Oakley CM; Nihoyannopoulos P
    Am J Cardiol; 1999 Nov; 84(9):1049-54. PubMed ID: 10569662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
    Kristen AV; Maurer MS; Rapezzi C; Mundayat R; Suhr OB; Damy T;
    PLoS One; 2017; 12(4):e0173086. PubMed ID: 28384285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
    Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Colby C; Laumann K; Zeldenrust SR; Leung N; Dingli D; Greipp PR; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Gertz MA
    J Clin Oncol; 2012 Mar; 30(9):989-95. PubMed ID: 22331953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.
    Sperry BW; Vranian MN; Hachamovitch R; Joshi H; Ikram A; Phelan D; Hanna M
    J Am Heart Assoc; 2016 Mar; 5(3):e002877. PubMed ID: 27013539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the Boston University staging system in AL amyloidosis.
    Tomlinson R; Matigian N; Mollee P
    Amyloid; 2019 Sep; 26(3):125-127. PubMed ID: 31145007
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.